Skip to content
  • About Us
    • Management
    • Board of Directors
    • Clinical and Scientific Advisory Board
    • Alliances and Community
  • Careers
  • Lead Technology
  • Publications
  • Investors
  • Expanded Access Policy
  • Contact Us
  • About Us
    • Management
    • Board of Directors
    • Clinical and Scientific Advisory Board
    • Alliances and Community
  • Careers
  • Lead Technology
  • Publications
  • Investors
  • Expanded Access Policy
  • Contact Us

Vasculotide, an Angiopoietin-1 mimetic, reduces acute skin ionizing radiation damage in a preclinical mouse model.

  • Post author:gtmrick
  • Post published:January 7, 2019
  • Post category:

Korpela E, Yohan D, Chin LC, Kim A, Huang X, Sade S, Van Slyke P, Dumont DJ, Liu SK. BMC Cancer. 2014 Aug 26;14:614 https://www.ncbi.nlm.nih.gov/pubmed/25159192

Continue ReadingVasculotide, an Angiopoietin-1 mimetic, reduces acute skin ionizing radiation damage in a preclinical mouse model.

Recent Posts

  • Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001
  • American Thoracic Society Selects Vasomune Therapeutics Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summit
  • AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study
  • Vasomune and AnGes Announce First Patient Enrolled in Phase 2a Clinical Study Evaluating AV-001 for the Treatment of Severe COVID-19 Disease
  • Vasomune Announces Government Financial Support for the Development of COVID-19 Therapeutic

Recent Comments

    Archives

    • May 2024
    • April 2024
    • November 2023
    • January 2022
    • November 2021
    • March 2021
    • December 2020
    • November 2020
    • August 2020
    • May 2020
    • March 2020
    • February 2020
    • January 2020
    • August 2018
    • December 2017
    • June 2015

    Categories

    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    About

    Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.

    Vasomune Therapeutics 2025 © All Rights Reserved.